Quieter news day, so it is a good moment to step back and appreciate what Lilly is doing, because the scale of it is genuinely without precedent.
BioPharma Dive tallied it cleanly: with the AtaiBeckley purchase, Lilly has now acquired eleven drug companies outright in 2026, by far the most of any pharmaceutical company. We have been loosely calling AtaiBeckley Lilly’s fifteenth deal, and it is worth being precise about the difference. Eleven of those are full acquisitions of companies. The rest are licensing deals and collaborations—Haisco, Abbisko, and others. Either way you count it, no one else is close.
The acquisitions span obesity, oncology, cell therapy, gene editing, vaccines, pain, and now psychedelics. The engine behind it is the GLP 1 franchise, which throws off enough cash to fund a continuous buying program that has reshaped the competitive landscape of the entire industry. Every target knows the most motivated buyer in the market is always shopping, and that knowledge alone changes what assets are worth.
The strategic question this raises is no longer whether Lilly can find deals. It is whether Lilly can integrate and execute across this many therapeutic areas at once. That is the question we will be listening for on the earnings calls that start this week.
Eleven Acquisitions in Seven Months: The Scope of What Lilly Is Doing
The list tells the story better than any summary can.
Orna Therapeutics: Circular RNA in vivo CAR T for autoimmune disease. Centessa Pharmaceuticals: Narcolepsy. Kelonia Therapeutics: Lentiviral in vivo CAR T for myeloma. CrossBridge Bio: Dual payload ADC technology. Ajax Therapeutics: Type II JAK2 inhibitor for myelofibrosis, data showed it “working right out of the gate.” Profluent Bio: AI designed recombinases for gene editing. Engage Biologics: Non viral DNA delivery. Curevo Vaccine: Shingles vaccine. LimmaTech Biologics: Bacterial vaccines for AMR pathogens. Vaccine Company Inc: EBV vaccine. AtaiBeckley: Psychedelic based mental health ($2.8 billion upfront, up to $3.8 billion total).
That is not counting Ascidian Therapeutics (RNA exon editing for kidney disease), Haisco ($3 billion plus, five programs), Abbisko (strategic collaboration across multiple targets), or the Sangamo bankruptcy auction where Lilly emerged as a stalking horse bidder for the Fabry gene therapy.
Eleven companies acquired. At least four major licensing deals. More than $30 billion in total disclosed deal value. Ten therapeutic areas. Eight modalities. Seven months.
What Makes This Different from Normal Pharma M&A
Large pharmaceutical companies always acquire. AbbVie bought Apogee for $10.9 billion. GSK bought Nuvalent for $10.6 billion. Vertex bought Crinetics for $10 billion. Those are big deals, but they are single transactions focused on specific therapeutic needs. What Lilly is doing is fundamentally different in both pace and breadth. It is not making one or two large bets per year. It is running a continuous acquisition program that touches nearly every major therapeutic area and modality in the industry simultaneously.
The closest historical comparison might be Pfizer in the early 2000s, when it absorbed Warner Lambert, Pharmacia, and Wyeth in rapid succession. But those were consolidation plays—buying established businesses for their existing revenue. Lilly is buying innovation, not revenue. Most of the eleven acquired companies have no approved products. They have science, platforms, and pipeline assets that Lilly believes can produce the next generation of medicines across diseases that range from cancer to mental health to kidney disease to infectious disease.
The GLP 1 franchise funds all of it. Zepbound and Foundayo are generating the kind of cash flow that lets a company absorb risk across multiple therapeutic areas without betting the balance sheet on any single program. If three of the eleven acquisitions produce meaningful drugs, Lilly has won. The other eight are options that did not pay off, absorbed by a cash flow that can handle the write downs.
The Integration Question
Every acquisition adds programs, people, and complexity. The company is betting that its scale lets it place more shots on goal than anyone else and absorb the misses. That is a defensible bet while the obesity cash keeps flowing.
But integration is where acquisition strategies usually face their hardest test. Each acquired company brings its own scientists, its own culture, its own way of doing things. Absorbing one or two acquisitions per year gives an organization time to onboard the people, align the priorities, and let the programs find their rhythm inside the larger company. Absorbing eleven in seven months compresses that timeline to a point where some acquired programs will inevitably receive less attention than they need.
The risk does not show up immediately. It shows up in two to three years, when the acquired programs are supposed to be producing Phase 2 and Phase 3 data and the ones that were deprioritized or poorly integrated produce less than the acquisition spend implied. Lilly’s December 7 Investment Community Meeting will be the first real opportunity for management to explain how eleven acquisitions across ten therapeutic areas integrate into a coherent strategy and which programs are being prioritized for advancement.
Q2 Earnings: The Numbers Have to Back Up the Mood
J&J opened earnings season with oncology sales missing expectations and shares slipping. That is one company and one quarter, and it would be a mistake to draw broad conclusions from a single print. But it sets a tone.
The pharmaceutical industry enters Q2 earnings in its best spirits in years. Record M&A. Thirteen IPOs raising $4.1 billion. A friendlier FDA under acting leadership. PwC declaring the ecosystem “back to full health.” The mood at BIO described as the most optimistic in years. Biotech public debuts have already eclipsed all of 2025.
All of that is real. But Q2 earnings are where the rhetoric meets the numbers, and the numbers are what actually determine whether the optimism is earned. The big pharmas report over the next two weeks, and we are tracking three threads through the calls.
Dealmaking signals. With the M&A wave running at historic pace, every management team will be asked whether they plan to keep buying. How aggressively they lean into more deals versus returning cash through buybacks sets the market’s expectations for the second half.
China exposure. With the congressional probe responses freshly submitted and the Biotech Investment National Security Act still pending, analysts will press on China strategy. The gap between what executives say on earnings calls and what their companies actually do remains the most reliable signal.
GLP 1 trajectory. For Lilly and Novo specifically, the questions are about supply, Medicare Bridge enrollment since the July 1 launch, retatrutide’s filing timeline, and the competitive dynamics between Foundayo, Zepbound, and Wegovy across the U.S. and Europe. These franchises carry an enormous share of the market’s growth expectations. The Q2 prints will either validate that weight or raise questions about it.
BMS’s KarXT Readout Is a $14 Billion Referendum
The most consequential binary event of late July is BMS’s KarXT readout in Alzheimer’s psychosis. This is not just a pipeline catalyst. It is the clearest test yet of whether BMS’s roughly $14 billion Karuna Therapeutics acquisition pays off.
KarXT represents a new mechanism in neuropsychiatry—a muscarinic receptor agonist combined with a peripheral muscarinic antagonist—that was designed to address psychotic and cognitive symptoms through a pathway completely different from the dopamine blocking antipsychotics that have dominated the field for decades. The drug is already approved and marketed in schizophrenia, where it demonstrated efficacy without the metabolic side effects that plague existing antipsychotics.
The Alzheimer’s psychosis readout tests the expansion thesis. BMS paid $14 billion for Karuna not because of schizophrenia alone, but because the company believed KarXT’s mechanism could expand across multiple neuropsychiatric conditions. Alzheimer’s psychosis—the hallucinations, delusions, and agitation that affect many Alzheimer’s patients and have almost no good treatment options—is the first test of that belief.
A positive result would do two things. It would open a large new indication with significant unmet need, expanding KarXT’s addressable population well beyond schizophrenia. And it would validate the thesis that the muscarinic mechanism has broad applicability across neuropsychiatric disease, setting up future expansion into other conditions.
A miss would narrow KarXT to its schizophrenia base for now and raise questions about how much of the $14 billion acquisition price was justified by expansion potential that did not materialize. It would not destroy the drug’s commercial future—schizophrenia is a real market—but it would reduce the ceiling and add to the long list of neuropsychiatry disappointments we have chronicled this year. Neumora dropped navacaprant after a Phase 3 miss. Merck killed its Alzheimer’s program for futility. The GSK/Alector pact ended after both drugs failed. Biogen’s tau data validated the science but missed the primary endpoint. The field keeps humbling the companies that try it.
The late July readout is the date to mark. We will cover the result when it arrives.
ESMO Is Coming Into View
Companies are beginning to announce their presentations for the ESMO Congress 2026, the fall’s biggest oncology meeting. Early disclosures are starting to surface, and the abstract landscape will firm up over the coming weeks.
ESMO tends to be where the year’s important cancer data lands after ASCO in the spring. This year, the meeting will be a venue for several storylines we have tracked since January:
RAS programs. Revolution Medicines’ daraxonrasib is now approved and commercially available. Genentech’s divarasib beat the approved standard in KRAS G12C lung cancer. Revolution’s zoldonrasib showed 82% response rates in first line pancreatic cancer. Updated data from any of these programs would shape the competitive landscape heading into 2027.
ADCs. Merck’s sac TMT has two Phase 3 wins and global filings expected this half. Enhertu keeps expanding. Novartis just bought Myricx’s payload platform for $1.5 billion. Updated data and new program disclosures will be closely watched.
China originated oncology assets. With 100 plus licensing pacts between Chinese drugmakers and U.S. companies, many of these assets are advancing toward registrational data. ESMO is where several will present updated results, and the quality of the data will determine whether the political friction around China sourcing has any clinical basis or is purely geopolitical.
Type 1 Diabetes Is Quietly Closing In on Insulin Independence
A BioSpace analysis found the type 1 diabetes pipeline is making remarkable progress toward functional insulin independence, driven by cell therapies that aim to replace the insulin producing beta cells that the disease’s autoimmune attack destroys.
This is worth pausing on. Type 1 diabetes is not the metabolic disease that GLP 1s treat. It is an autoimmune disease where the body destroys its own insulin producing cells, leaving patients dependent on injected insulin for survival from the moment of diagnosis—often in childhood—for the rest of their lives. A functional cure, where transplanted or engineered cells produce insulin on their own, would be one of the most significant advances in metabolic medicine in a generation.
Vertex is among the companies furthest along with a cell therapy approach, part of the diversification strategy we covered when it bought Crinetics for endocrinology and Pharming for hereditary angioedema. A Vertex type 1 diabetes program that achieves insulin independence in patients would validate the company’s thesis that it can extend the precision medicine approach it mastered in cystic fibrosis to other genetically defined diseases.
The progress is real but the challenges remain substantial. Immune rejection of transplanted cells, durability of the cell therapy, manufacturing complexity, and the logistics of delivering a cell based treatment at scale are all unsolved at the registrational level. But the direction of travel is unmistakably toward a therapy that replaces what the disease takes away, and the field is closer than it has been at any point in the history of type 1 diabetes research.
Strategic Themes
1. Eleven Acquisitions Is Not a Strategy—It Is a New Operating Model
Normal pharmaceutical companies make one or two acquisitions per year. Lilly made eleven in seven months. That is not an M&A strategy running hot. It is a new way of building a pharmaceutical company, where external innovation is the primary source of pipeline growth rather than a supplement to internal R&D. The model depends on the GLP 1 franchise continuing to generate the cash that funds it and on the organization’s ability to manage the complexity that eleven acquired companies create. Both of those dependencies are real risks, but neither has broken yet, and the sheer breadth of what Lilly is assembling has no modern comparison.
2. Q2 Earnings Are the First Real Test of Whether the Industry’s Optimism Is Earned
Record M&A. Healthy IPOs. Friendlier FDA. “Back to full health.” The narrative has been uniformly positive for months. J&J’s oncology miss is a reminder that individual businesses still have to execute regardless of the macro environment. Over the next two weeks, the earnings prints will show whether the optimism is broadly shared across the sector or concentrated in the companies that happen to be executing well.
3. The KarXT Readout Will Shape How the Market Prices Neuropsychiatry for the Rest of the Year
Alzheimer’s psychosis is a large, under treated indication where almost nothing works. If KarXT succeeds, it validates BMS’s $14 billion Karuna bet and reopens the door for investment in neuropsychiatry after years of failure. If it misses, it adds another entry to the longest losing streak in drug development. The late July readout is the most important binary event in CNS this summer.
4. Type 1 Diabetes Deserves More Attention Than the GLP 1 Noise Allows
The GLP 1 story dominates metabolic disease coverage, and for good reason: it is the biggest commercial opportunity in the industry. But the type 1 diabetes pipeline is pursuing something more profound—a functional cure for a lifelong autoimmune disease that affects millions of people, most of whom were diagnosed as children. The progress toward insulin independence through cell therapy is quietly remarkable, and the companies furthest along (Vertex among them) are building toward a therapeutic milestone that would rank among the most important in the history of medicine.
Frequently Asked Questions
How many companies has Lilly acquired in 2026?
Eleven outright acquisitions, by far the most of any pharma company. Plus at least four major licensing deals (Haisco, Abbisko, and others). Total disclosed deal value exceeds $30 billion across ten therapeutic areas and eight modalities.
What is the KarXT readout?
BMS’s muscarinic receptor drug KarXT (already approved in schizophrenia) is expected to read out in Alzheimer’s psychosis in late July. The result tests whether the roughly $14 billion Karuna acquisition pays off through label expansion beyond schizophrenia into a large, under treated neuropsychiatric indication.
How did J&J’s earnings look?
Shares slipped as oncology sales missed expectations, opening Q2 earnings season with a cautionary note. The big pharmas report over the next two weeks.
When is ESMO?
Abstracts are beginning to surface. ESMO Congress 2026 is the fall’s biggest oncology meeting and will feature updated data on RAS programs, ADCs, and China originated oncology assets.
What is happening in type 1 diabetes?
Cell therapies are making real progress toward functional insulin independence by replacing the insulin producing cells the disease destroys. Vertex is among the companies furthest along. A functional cure would be one of the most significant advances in metabolic medicine.
What is the next major catalyst?
Late July: BMS KarXT Alzheimer’s psychosis readout and PTC sepiapterin PKU readout. July 31: Section 232 pharma tariffs effective for large companies. August: Replimune RP1 FDA response.
BioMed Nexus Pro — What Institutional Subscribers Are Reading Today
Lilly Bought Eleven Companies in Seven Months. We analyze the integration risk that nobody is pricing, assess whether the continuous acquisition model works at this scale, and identify where the strategy could crack if the GLP 1 cash flow trajectory shifts.
KarXT Is a $14B Referendum. We detail what a win or miss in Alzheimer’s psychosis means for BMS, the Karuna acquisition thesis, and how investors should price the entire neuropsychiatry space heading into the fall.
Q2 Earnings: What Actually Matters. We map the franchises most likely to disappoint this quarter, identify the three questions worth listening for on the calls, and assess whether J&J’s soft open is an isolated stumble or a preview of broader competitive pressure.
Plus: ESMO preview, type 1 diabetes pipeline, PTC sepiapterin PKU, Section 232 countdown (10 days), and the full H2 catalyst calendar.
About BioMed Nexus
BioMed Nexus delivers institutional grade intelligence to biotech and pharma executives, investors, and clinicians. Our daily briefings and deep dive analyses cut through the noise to deliver the strategic insights that drive better decision making in the life sciences.
Subscribe to receive daily updates and gain access to BioMed Nexus Pro institutional intelligence briefs.
